GO:1903003 positive regulation of protein deubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903003 describes any process that activates or increases the frequency, rate or extent of protein deubiquitination, the removal of ubiquitin from substrate proteins.
• Positive regulation of deubiquitination is frequently achieved by phosphorylation-driven feedback loops, such as the CHK2-USP7 axis that stabilizes p53 under oxidative stress.
• Deubiquitinases (DUBs) such as OTUD6A, USP7, USP5, USP48, USP43, USP2 and USP1 are central effectors whose upregulation or activation drives cancer progression and therapy resistance.
• CRISPR screens have emerged as powerful tools to identify positive regulators of deubiquitination, including USP1 as a regulator of MAST1-driven cisplatin resistance and modulators of Foxp3 in regulatory T cells.
• Dysregulated positive regulation of deubiquitination contributes to tumorigenesis, chemoresistance, immune evasion and metabolic reprogramming, making it a high-value target space for therapeutic intervention.
• Studying GO:1903003 requires integrated approaches including knockout, point-mutation, knock-in and overexpression cell models combined with proteomics and functional assays.
Description
Protein ubiquitination is a reversible post-translational modification that controls protein stability, localization and activity. The reverse process, deubiquitination, is catalyzed by deubiquitinases (DUBs) and removes ubiquitin chains from substrate proteins. GO:1903003, positive regulation of protein deubiquitination, refers to any process that activates or increases the frequency, rate or extent of this removal reaction. This regulatory node is critical because it determines the half-life and function of key oncoproteins and tumor suppressors, thereby influencing cell fate decisions.
positive regulation of protein deubiquitination At A Glance
| GO ID | GO:1903003 |
|---|---|
| GO term | positive regulation of protein deubiquitination |
| Ontology | biological_process |
| Synonym | activation of deubiquitination; upregulation of protein deubiquitination; positive regulation of protein deubiquitylation |
| Major function | Increases the rate or extent of ubiquitin removal from substrate proteins, thereby stabilizing or modulating their activity |
| Related DUBs | OTUD6A, USP7, USP5, USP48, USP43, USP2, USP1 |
| Disease relevance | Cancer progression, chemoresistance, immune evasion, metabolic reprogramming |
| Research methods | CRISPR knockout/knock-in screens, proteomics, ubiquitination assays |
What Is GO:1903003?
GO:1903003 is a biological process term defined as any process that activates or increases the frequency, rate or extent of protein deubiquitination. In practical terms, it encompasses molecular events such as phosphorylation of a DUB that enhances its catalytic activity, recruitment of a DUB to a substrate, or upregulation of DUB expression that collectively shift the balance toward ubiquitin removal from target proteins.
Why Is positive regulation of protein deubiquitination Important in Cell Biology?
Positive regulation of protein deubiquitination is a central mechanism for controlling protein stability and signaling dynamics. It is frequently hijacked in cancer to stabilize oncoproteins such as CDC6, c-Myc and PD-L1, leading to tumor progression, chemoresistance and immune evasion. Understanding how this process is regulated provides opportunities for therapeutic intervention, particularly through targeting DUBs or their upstream activators.
• Controls the stability of oncoproteins and tumor suppressors, directly impacting cancer cell survival.
• Drives chemoresistance by stabilizing proteins such as CDC6 and MAST1.
• Promotes immune evasion through stabilization of PD-L1.
• Regulates metabolic reprogramming, including glycolysis, via c-Myc stabilization.
• Modulates inflammatory cell death pathways such as pyroptosis through Gasdermin E stabilization.
• Is essential for oxidative stress responses via the CHK2-USP7-p53 axis.
• Represents a druggable node for small-molecule DUB inhibitors.
• Can be systematically interrogated using CRISPR screens to identify novel regulators.
What Happens During positive regulation of protein deubiquitination?
Activation of Deubiquitinases by Phosphorylation
In simple terms: A kinase adds a phosphate tag to a deubiquitinase, turning it on so it can remove ubiquitin from target proteins.
Phosphorylation of DUBs is a common mechanism for positive regulation. For example, under oxidative stress, CHK2 phosphorylates USP7, enhancing its deubiquitinase activity toward p53, which stabilizes p53 and promotes cell survival. This phosphorylation-deubiquitination positive feedback loop illustrates how upstream signaling can amplify deubiquitination.
Recruitment of DUBs to Substrate Proteins
In simple terms: The deubiquitinase is brought close to the protein it needs to edit.
Positive regulation can occur through increased recruitment of DUBs to specific substrates. OTUD6A interacts with and deubiquitinates CDC6, promoting its stabilization and tumor progression. Similarly, USP43 stabilizes c-Myc by removing ubiquitin chains, enhancing glycolysis and metastasis in bladder cancer.
Upregulation of DUB Expression
In simple terms: The cell makes more of the deubiquitinase enzyme, so more ubiquitin is removed.
Increased transcription or translation of DUBs can positively regulate deubiquitination. USP2 is upregulated in tumors and stabilizes PD-L1, leading to immune evasion. USP48 stabilization of Gasdermin E promotes pyroptosis in cancer cells, indicating that DUB abundance directly impacts cell death pathways.
Palmitoylation-Dependent Regulation of DUBs
In simple terms: A fatty acid modification helps the deubiquitinase do its job.
FASN-mediated palmitoylation of USP5 enhances its ability to deubiquitinate GPX4, thereby inhibiting ferroptosis in breast cancer. This demonstrates that lipid modifications can positively regulate DUB function and downstream substrate stability.
Key Genes Involved in GO:1903003 positive regulation of protein deubiquitination
The following genes and proteins are experimentally validated participants in positive regulation of protein deubiquitination, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OTUD6A | Deubiquitinates CDC6, promoting tumor progression and chemoresistance | Target for overcoming chemoresistance in cancers with CDC6 overexpression |
| USP7 | Phosphorylated by CHK2, stabilizes p53 under oxidative stress | Model for studying phosphorylation-deubiquitination feedback loops |
| USP5 | Palmitoylated by FASN, deubiquitinates GPX4 to inhibit ferroptosis | Potential target in breast cancer metabolism and ferroptosis |
| USP48 | Stabilizes Gasdermin E to promote pyroptosis | Modulator of inflammatory cell death in cancer |
| USP43 | Stabilizes c-Myc, promoting glycolysis and metastasis | Target in bladder cancer metabolism and metastasis |
| USP2 | Deubiquitinates and stabilizes PD-L1, promoting immune evasion | Target for cancer immunotherapy |
| USP1 | Regulates MAST1-driven cisplatin resistance | Biomarker and target for cisplatin resistance |
| CHK2 | Phosphorylates USP7 to enhance p53 stabilization | Upstream regulator in oxidative stress response |
| FASN | Palmitoylates USP5 to enhance GPX4 deubiquitination | Link between lipid metabolism and ferroptosis |
| CDC6 | Substrate of OTUD6A; stabilization promotes tumor progression | Readout for OTUD6A activity |
| GPX4 | Substrate of USP5; stabilization inhibits ferroptosis | Key regulator of ferroptosis |
| Gasdermin E | Substrate of USP48; stabilization promotes pyroptosis | Effector of pyroptosis |
| c-Myc | Substrate of USP43; stabilization drives glycolysis | Oncogenic transcription factor |
| PD-L1 | Substrate of USP2; stabilization causes immune evasion | Immune checkpoint ligand |
| MAST1 | Substrate of USP1; stabilization causes cisplatin resistance | Kinase involved in chemoresistance |
| Foxp3 | Modulated by DUBs identified in CRISPR screens | Regulatory T cell master transcription factor |
How Is positive regulation of protein deubiquitination Regulated?
Positive regulation of protein deubiquitination is itself tightly regulated at multiple levels. Upstream kinases such as CHK2 can phosphorylate DUBs to enhance their activity, as shown for USP7 under oxidative stress. Metabolic enzymes like FASN can modify DUBs via palmitoylation, altering their function. Additionally, DUB expression levels are controlled transcriptionally and post-translationally, and their localization to specific substrates is often mediated by scaffold proteins. These layers of regulation ensure that deubiquitination is context-dependent and reversible.
positive regulation of protein deubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUD6A | Tumor progression and chemoresistance | Knockout and overexpression in cancer cell lines |
| USP2 | Immune evasion via PD-L1 stabilization | Knockout in melanoma or lung cancer models |
| USP5 | Ferroptosis inhibition in breast cancer | Point mutation of palmitoylation site |
| USP1 | Cisplatin resistance | CRISPR knockout in resistant cancer cells |
| USP48 | Pyroptosis regulation | Knock-in of tagged USP48 for localization studies |
Cancer Progression and Chemoresistance
Positive regulation of deubiquitination frequently stabilizes oncoproteins. OTUD6A-mediated deubiquitination of CDC6 promotes tumor progression and chemoresistance. USP43 stabilizes c-Myc to drive glycolysis and metastasis in bladder cancer. USP1 regulates MAST1-driven cisplatin resistance, highlighting its role in therapy failure.
Immune Evasion and Immunotherapy
USP2 deubiquitinates and stabilizes PD-L1, leading to immune evasion in tumors. This connects positive regulation of deubiquitination directly to immune checkpoint regulation and suggests that targeting such DUBs could enhance immunotherapy efficacy.
Ferroptosis and Metabolic Stress
FASN-mediated palmitoylation of USP5 enhances GPX4 deubiquitination, inhibiting ferroptosis in breast cancer. This links lipid metabolism to cell death resistance and identifies USP5 as a potential therapeutic target.
Inflammatory Cell Death
USP48 stabilizes Gasdermin E to promote pyroptosis in cancer cells. This demonstrates that positive regulation of deubiquitination can also promote inflammatory cell death, with implications for cancer therapy.
From positive regulation of protein deubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of OTUD6A reduce CDC6 stability and chemoresistance? | OTUD6A knockout cell line |
| Does phosphorylation of USP7 at specific sites enhance p53 stabilization? | USP7 point-mutation knock-in |
| Does palmitoylation of USP5 regulate GPX4 deubiquitination? | USP5 palmitoylation-deficient mutant |
| Can overexpression of USP2 drive PD-L1 stabilization and immune evasion? | USP2 overexpression in tumor cells |
| Which DUBs regulate Foxp3 stability? | CRISPR screen in regulatory T cells |
| Does USP1 knockout reverse MAST1-driven cisplatin resistance? | USP1 knockout in resistant cancer cells |
How to Study the positive regulation of protein deubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on deubiquitination | Identify positive regulators |
| Ubiquitination assay | Removal of ubiquitin chains from substrate | Validate DUB activity |
| Phosphorylation assay | Kinase-mediated DUB activation | Study CHK2-USP7 axis |
| Palmitoylation assay | Lipid modification of DUBs | Study FASN-USP5 axis |
| Ferroptosis assay | Cell death via lipid peroxidation | Assess GPX4 stabilization |
| Pyroptosis assay | Inflammatory cell death | Assess Gasdermin E stabilization |
| Glycolysis assay | Metabolic flux | Assess c-Myc stabilization |
| Immune evasion assay | T cell killing | Assess PD-L1 stabilization |
CRISPR Screens for Deubiquitinase Regulators
Genome-wide CRISPR screens have been used to identify modulators of deubiquitination. A screen in regulatory T cells revealed modulators of Foxp3, including DUBs. Another screen focused on the deubiquitinase subfamily identified USP1 as a regulator of MAST1-driven cisplatin resistance. These approaches enable unbiased discovery of positive regulators.
Proteomics and Ubiquitination Assays
Mass spectrometry-based proteomics can quantify changes in ubiquitination and deubiquitination on specific substrates. For example, OTUD6A-mediated deubiquitination of CDC6 was demonstrated using ubiquitination assays. Similarly, USP5-dependent GPX4 deubiquitination was shown by immunoprecipitation and ubiquitin chain analysis.
Functional Assays for Cell Death and Metabolism
Ferroptosis, pyroptosis, glycolysis and metastasis assays are used to link deubiquitination to phenotypes. FASN-USP5-GPX4 axis was studied using ferroptosis inducers. USP48-Gasdermin E pyroptosis was assessed by cell death assays. USP43-c-Myc glycolysis was measured by metabolic flux.
Imaging and Localization Studies
Fluorescence microscopy and tagged knock-in models can track DUB localization and substrate interactions. For example, tagged USP48 knock-in allows visualization of Gasdermin E stabilization. These methods complement biochemical assays.
How CRISPR Can Be Used to Study GO:1903003 positive regulation of protein deubiquitination
Knockout
CRISPR knockout of DUBs such as OTUD6A, USP1 or USP2 can abolish positive regulation of deubiquitination, leading to substrate destabilization and reduced tumor growth or chemoresistance. Knockout models are essential for establishing causality.
Point Mutation
Point mutations can be introduced to disrupt specific regulatory sites, such as phosphorylation or palmitoylation sites on DUBs. For example, mutation of USP7 phosphorylation sites can prevent CHK2-mediated activation. Similarly, mutation of USP5 palmitoylation site can block FASN-dependent regulation.
Knock-in
Knock-in of tagged DUBs (e.g., GFP or HA) allows for localization and interaction studies. Tagged USP48 knock-in can reveal its dynamics during pyroptosis. Knock-in of mutant DUBs can also model disease-associated variants.
Overexpression
Overexpression of DUBs such as USP2 or USP43 can drive substrate stabilization and phenotypic changes like immune evasion or metastasis. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of protein deubiquitination Research
Researchers studying positive regulation of protein deubiquitination-related genes often need to determine whether a candidate gene is causally involved in substrate stabilization, disease progression or therapy response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of protein deubiquitination research.
Frequently Asked Questions About positive regulation of protein deubiquitination
What is GO:1903003?
GO:1903003 is the Gene Ontology term for positive regulation of protein deubiquitination, defined as any process that activates or increases the frequency, rate or extent of protein deubiquitination.
What genes are involved in positive regulation of protein deubiquitination?
Key genes include OTUD6A, USP7, USP5, USP48, USP43, USP2 and USP1, as well as upstream regulators like CHK2 and FASN.
How is protein deubiquitination positively regulated?
It can be positively regulated by phosphorylation of DUBs (e.g., CHK2-USP7), palmitoylation (e.g., FASN-USP5), increased DUB expression, or enhanced recruitment to substrates.
What diseases are associated with dysregulated deubiquitination?
Dysregulated deubiquitination is linked to cancer progression, chemoresistance, immune evasion, ferroptosis resistance and inflammatory cell death.
How can CRISPR screens identify regulators of deubiquitination?
CRISPR screens can knockout or activate genes genome-wide to identify DUBs or upstream factors that modulate substrate stability, as shown for USP1 and Foxp3.
What is the role of USP7 in deubiquitination?
USP7 is phosphorylated by CHK2 under oxidative stress, which enhances its deubiquitinase activity toward p53, stabilizing p53.
How does USP5 regulate ferroptosis?
USP5 is palmitoylated by FASN, which enhances its deubiquitination of GPX4, thereby inhibiting ferroptosis in breast cancer.
What is the link between deubiquitination and immune evasion?
USP2 deubiquitinates and stabilizes PD-L1, leading to immune evasion by tumor cells.
Can deubiquitination be targeted therapeutically?
Yes, DUBs such as USP1 and OTUD6A are potential therapeutic targets for overcoming chemoresistance and tumor progression.
What models are used to study positive regulation of deubiquitination?
Common models include CRISPR knockout, point mutation, knock-in and overexpression cell lines, combined with ubiquitination assays, proteomics and functional readouts.
Conclusion
GO:1903003, positive regulation of protein deubiquitination, is a critical biological process that controls protein stability and signaling in health and disease. Its dysregulation contributes to cancer progression, chemoresistance and immune evasion, making it a promising target for therapeutic intervention. Advances in CRISPR screening and genome editing are accelerating the discovery of new regulators and the development of targeted therapies.
References
- 1. Cui J et al.. 2024. Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance.. Mol Cancer 23(1):86 PMID: 38685067
- 2. Liu J et al.. 2024. The phosphorylation-deubiquitination positive feedback loop of the CHK2-USP7 axis stabilizes p53 under oxidative stress.. Cell Rep 43(6):114366 PMID: 38879877
- 3. Qian Z et al.. 2025. FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination.. J Exp Clin Cancer Res 44(1):289 PMID: 41088402
- 4. Ren Y et al.. 2023. USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer.. Cancer Res 83(7):1074-1093 PMID: 36607699
- 5. Li M et al.. 2024. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer.. Cell Death Dis 15(1):44 PMID: 38218970
- 6. Kuang Z et al.. 2023. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1.. Cell Death Differ 30(10):2249-2264 PMID: 37670038
- 7. Cortez JT et al.. 2020. CRISPR screen in regulatory T cells reveals modulators of Foxp3.. Nature 582(7812):416-420 PMID: 32499641
- 8. Tyagi A et al.. 2022. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.. Theranostics 12(13):5949-5970 PMID: 35966591
